company EW - SteadyBase

steadybase-$ company EW

account_id none on file

legal_name Edwards Lifesciences Corp

ticker EW

cik 1099800

domain edwards.com

linkedin_company_url https://www.linkedin.com/company/edwards-lifesciences

entry_point_account_id none on file

name Edwards Lifesciences Corporation

exchange NYSE

sector Health Care

hq Irvine, CA, United States

irhttps://ir.edwards.com/overview/default.aspx

sector index/company/sector/health-care/

calls 6 filings 40 executives 4 family 0

why_nownone on file

calls

Yeah, so we do think gross margin has room to improve from here, as does operating margin. Keep in mind, we're already starting from relatively strong margins compared to our industry. So our priority has been investing aggressively on internal growth more so than on trying to expand margins. But I do think there's going to be opportunity for those margins to gradually incrementally slowly expand over time and it's something that we that we try to think carefully about short term though to your question about covid you know it's been remarkable our our margins have remained pretty stable despite the fact that sales are down relative relative to pre-covered levels because expenses are down as well largely driven by things that are happening out in the field so travel meetings, attendance at various different societies and events. And so it's been kind of a natural hedge against the sales headwinds that we've seen from COVID and we're benefiting from that. To be honest though, we'd like to see expenses go back up along with sales because it's an indication that the environment is more normalized, that we're able to invest aggressively, that we can enroll our clinical trials. at the higher rates that we saw pre-COVID. And so that's sort of the way we're thinking about margins overall.

Oct 27, 2021 / receipt, needs a key / Scott, CFO | earnings call 2021-10-27 | transcript b897e95b-2537-4957-91b3-51a5126e414c | chars 27236-28538 | segment 27

It doesn't help right now that some of us can't travel to China, and so those kind of things tend to be obstacles, but overall a team that's out there executing.

Jul 30, 2021 / receipt, needs a key / Mike, other | earnings call 2021-07-30 | transcript f53cd3b3-2b2b-477f-8f8b-66ea684cb60b | chars 44121-44282 | segment 44

As our business continues to rebound from the impact of COVID, we expect sales to strengthen and expenses to grow as travel and clinical trials ramp up.

Apr 20, 2021 / receipt, needs a key / Scott, CFO | earnings call 2021-04-20 | transcript aad94580-e93a-4bc7-ae4d-f07e7f478eb7 | chars 16846-16998 | segment 16

As I mentioned earlier, we anticipate our spending will increase during the year as travel restrictions subside and we resume a more normalized operating environment.

Apr 20, 2021 / receipt, needs a key / Scott, CFO | earnings call 2021-04-20 | transcript aad94580-e93a-4bc7-ae4d-f07e7f478eb7 | chars 18217-18383 | segment 18

Well, it's early to talk about what our operating margins may look like in 2021, although I'll tell you, we're eager to get back to full pace of travel, of being out in the field, of being with customers, and of ramping our clinical trials back up to fully pre-COVID levels. We're anticipating that those expenses will ramp as quickly as we're allowed to do it.

Oct 22, 2020 / receipt, needs a key / Scott, CFO | earnings call 2020-10-22 | transcript b7f8a8bf-ab5e-43e3-bbab-8c058e79afd6 | chars 47750-48111 | segment 49

Some expenses decline naturally due to less travel and meeting expenses, as well as delayed clinical trial activity.

Apr 23, 2020 / receipt, needs a key / Scott, other | earnings call 2020-04-23 | transcript 38e321a0-fe6f-4a28-b705-4099f5ef1456 | chars 19677-19793 | segment 20

filings

Associate Product Manager, Marketing | {"ats": "workday", "city": null, "state": null, "job_id": "/job/Canada-Mississauga/Associate-Product-Manager--Marketing_Req-50845", "remote": false, "category":